Purpose: Ovarian cancer (OC) is the most lethal gynaecological cancer. Early detection is required to improve patient survival. Risk estimation models were constructed for Type I (Model I) and Type II (Model II) OC from analysis of Protein Z, Fibronectin, C-reactive protein and CA125 levels in prospectively collected samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Results: Model I identifies cancers earlier than CA125 alone, with a potential lead time of 3-4 years. Model II detects a number of high grade serous cancers at an earlier stage (Stage I/II) than CA125 alone, with a potential lead time of 2-3 years and assigns high risk to patients that the ROCA Algorithm classified as normal. Materials a...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...
Purpose: Ovarian cancer (OC) is the most lethal gynaecological cancer. Early detection is required t...
Background Ovarian cancer has a poor survival rate due to late diagnosis and improved methods are ne...
Background: There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). T...
There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). The purpose o...
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven effi...
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven effi...
CA125 is widely used as an initial investigation in women presenting with symptoms of possible ovari...
From MDPI via Jisc Publications RouterHistory: accepted 2021-06-06, pub-electronic 2021-06-09Publica...
Background: An early detection tool for EOC was constructed from analysis of biomarker expression da...
Purpose: About 60% of ovarian cancers are diagnosed at late stage,when 5-year survival is less than3...
CA125 is widely used as an initial investigation in women presenting with symptoms of possible ovari...
A panel of biomarkers may improve predictive performance over individual markers. Although many biom...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...
Purpose: Ovarian cancer (OC) is the most lethal gynaecological cancer. Early detection is required t...
Background Ovarian cancer has a poor survival rate due to late diagnosis and improved methods are ne...
Background: There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). T...
There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). The purpose o...
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven effi...
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven effi...
CA125 is widely used as an initial investigation in women presenting with symptoms of possible ovari...
From MDPI via Jisc Publications RouterHistory: accepted 2021-06-06, pub-electronic 2021-06-09Publica...
Background: An early detection tool for EOC was constructed from analysis of biomarker expression da...
Purpose: About 60% of ovarian cancers are diagnosed at late stage,when 5-year survival is less than3...
CA125 is widely used as an initial investigation in women presenting with symptoms of possible ovari...
A panel of biomarkers may improve predictive performance over individual markers. Although many biom...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in c...